Stay updated on Lenvatinib Combo with Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Combo with Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the Lenvatinib Combo with Pembrolizumab in Solid Tumors Clinical Trial page
- Check3 days agoChange DetectedThe site's footer revision label changed from v3.7.1 to v3.7.2, while the study page continues to display a 403 error.SummaryDifference0.2%

- Check10 days agoChange DetectedThe site footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study content. This indicates the page is temporarily inaccessible and blocks access to the study record.SummaryDifference0.5%

- Check31 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study content with a standard error page to indicate blocked access.SummaryDifference18%

- Check53 days agoChange DetectedThe study record adds an NIH grant/contract attribution for 2017. It also updates the revision tag from v3.6.5 to v3.6.6.SummaryDifference0.1%

- Check74 days agoChange DetectedThe changes add Revision: v3.6.5 and remove Revision: v3.6.4, indicating a minor update to the page's metadata.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib Combo with Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Combo with Pembrolizumab in Solid Tumors Clinical Trial page.